ABSTRACT
The successful application of radionanomedicine is based on the optimal labeling of radionuclide mainly on the surface of the core nanomaterials. For nano-toxicity, radionanomedicine will be a solution, which has the capability of dose reduction of nanomaterials administered, in vivo and can help them to expect and prevent the damaged organs from the understanding of the exact biodistribution of nanomaterials. In addition, the qualification or quantification is another key factor for in vivo application of hybrid nanomaterials, thus, the dosimetric analysis using radionanomedicine can help the exact qualification and quantification of hybrid nanomaterials. The simultaneous surface modification of nanoparticles with ligand and/or chelator and polyethylene glycol (PEG), if feasible, will make the production of the ligand and/ or chelator-bound and PEGylated nanoparticle easy. Ligands and chelators need to be added to the termini of PEGs or the surface of dextran.
